Activities per year
Abstract
Objectives
The coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Antibody testing plays a big role in understanding virus’s epidemiology and it reveals whether a patient’s immune system has developed antibodies against the virus. The main goal of this study was to evaluate antibody response to SARS-CoV-2 in dynamics.
Materials and Methods
In this study 155 patients (both hospitalized and outpatients) were analysed for the presence of virus-specific (IgG NCP, IgG S1 and IgA) antibodies using EUROIMMUN semi-quantitative ELISA. 168 patients’ plasma samples for virus-specific antibodies were quantified using quantitative ELISA (ANTIBODIES) for anti-SARS-CoV-2 IgG and IgM class antibodies.
Results
In 123 (79.35%) COVID-19 patients’ plasma samples anti-SARS-CoV-2 IgG NCP, in 122 (78.71%) - anti-SARS-CoV-2 IgG S1 and in 117 (75.48%) - anti-SARS-CoV-2 IgA class antibodies were detected. 23 of 155 patients had been tested for antibodies repeatedly. The highest number of IgA positive plasma samples were among those collected after 5-12 days, the lowest number – after 63 – 85 days from the disease onset. There are slight differences in the IgG antibody response to the two SARS-CoV-2 antigens (against S1 and NCP) tested. 168 patients had been tested for antibodies in dynamics. IgM class antibody titters decreased after about 2 months of observation. Also, a decreasing tendency of IgG class antibody titters in patients’ plasma samples was observed after about 2 months, but in some patient plasma samples IgG class antibodies remain detectable until ~6 months. In one patient sample collected after two months, IgM antibodies had reappeared.
Conclusion
IgM titter decreased after about 2 months when a decreasing tendency in some of the cases was also observed for IgG. In some cases, IgG antibodies remain detectable until ~6 months. Repeated IgM production can indicate a possible COVID-19 reinfection/reactivation in some patients.
The coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Antibody testing plays a big role in understanding virus’s epidemiology and it reveals whether a patient’s immune system has developed antibodies against the virus. The main goal of this study was to evaluate antibody response to SARS-CoV-2 in dynamics.
Materials and Methods
In this study 155 patients (both hospitalized and outpatients) were analysed for the presence of virus-specific (IgG NCP, IgG S1 and IgA) antibodies using EUROIMMUN semi-quantitative ELISA. 168 patients’ plasma samples for virus-specific antibodies were quantified using quantitative ELISA (ANTIBODIES) for anti-SARS-CoV-2 IgG and IgM class antibodies.
Results
In 123 (79.35%) COVID-19 patients’ plasma samples anti-SARS-CoV-2 IgG NCP, in 122 (78.71%) - anti-SARS-CoV-2 IgG S1 and in 117 (75.48%) - anti-SARS-CoV-2 IgA class antibodies were detected. 23 of 155 patients had been tested for antibodies repeatedly. The highest number of IgA positive plasma samples were among those collected after 5-12 days, the lowest number – after 63 – 85 days from the disease onset. There are slight differences in the IgG antibody response to the two SARS-CoV-2 antigens (against S1 and NCP) tested. 168 patients had been tested for antibodies in dynamics. IgM class antibody titters decreased after about 2 months of observation. Also, a decreasing tendency of IgG class antibody titters in patients’ plasma samples was observed after about 2 months, but in some patient plasma samples IgG class antibodies remain detectable until ~6 months. In one patient sample collected after two months, IgM antibodies had reappeared.
Conclusion
IgM titter decreased after about 2 months when a decreasing tendency in some of the cases was also observed for IgG. In some cases, IgG antibodies remain detectable until ~6 months. Repeated IgM production can indicate a possible COVID-19 reinfection/reactivation in some patients.
| Original language | English |
|---|---|
| Pages | 34 |
| Number of pages | 1 |
| Publication status | Published - 17 Jun 2021 |
| Event | 1st Conference of the Society for Virology: Tackling Global Viral Epidemics - Online Conference, South Africa Duration: 16 Jun 2021 → 18 Jun 2021 Conference number: 1 http://www.ws-virology.org https://wsv2021.com/ |
Conference
| Conference | 1st Conference of the Society for Virology |
|---|---|
| Abbreviated title | WSV 2021 |
| Country/Territory | South Africa |
| Period | 16/06/21 → 18/06/21 |
| Internet address |
Field of Science*
- 3.2 Clinical medicine
- 3.3 Health sciences
Publication Type*
- 3.4. Other publications in conference proceedings (including local)
Access to Document
Fingerprint
Dive into the research topics of 'Characterization Of Antibody Responses To SARS-CoV-2 Infection In Covid-19 Patients In Latvia'. Together they form a unique fingerprint.Activities
- 1 Oral presentation
-
Characterization Of Antibody Responses To SARS-CoV-2 Infection In COVID-19 Patients In Latvia
Strojeva, S. (Speaker), Grāvelsiņa, S. (Co-author), Sokolovska, L. (Co-author), Nora-Krūkle, Z. (Co-author), Čistjakovs, M. (Co-author) & Murovska, M. (Co-author)
16 Jun 2021 → 18 Jun 2021Activity: Talk or presentation types › Oral presentation